Initiator Pharma A/S OMXSTO:INIT:
Q1 2026 NET REVENUE WAS KDKK 0
Q1 2026 OPERATING LOSS, EBIT WAS KDKK -11,432
Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
Earlier from Initiator Pharma A/s
- Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study
- Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued
- Initiator Pharma To Fully Prioritize Pudafensine
- Initiator Pharma to present at Redeye Healthcare Day 2026